GlassScriptPhysician profile
Michael F Sweeney
NPI 1043200264
$1,295.90
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $418 · 2020: $85.88 · 2021: $123 · 2022: $87.28 · 2023: $478 · 2024: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $582.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $382.03 | 2019-2023 | Lo Loestrin Fe |
| Sumitomo Pharma America, INC. | $317.32 | 2023 | Myfembree |
| Astellas Pharma US INC | $106.21 | 2023-2024 | Veozah |
| Pfizer INC. | $100.64 | 2019-2022 | |
| Daiichi Sankyo INC. | $76.08 | 2019-2022 | |
| Therapeuticsmd, INC. | $65.53 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $50.37 | 2019 | |
| Exeltis, USA INC. | $42.96 | 2019 | |
| Coopersurgical, INC. | $37.13 | 2024 | Paragard T 380a |
| Bayer Healthcare Pharmaceuticals INC. | $30.27 | 2023 | |
| Mayne Pharma Commercial LLC | $28.63 | 2023 | |
| Ethicon US, LLC | $16.61 | 2020 | |
| Ferring Pharmaceuticals INC. | $15.53 | 2020 | |
| Vertical Pharmaceuticals, LLC | $13.62 | 2019 | |
| Allergan, INC. | $12.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sweeney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.